Results 31 to 40 of about 2,406,031 (343)
The Binding of Aripiprazole to Plasma Proteins in Chronic Renal Failure Patients
Toxins, 2021 The binding of drugs to plasma protein is frequently altered in certain types of renal diseases. We recently reported on the effects of oxidation and uremic toxins on the binding of aripiprazole (ARP) to human serum albumin.
Kenshiro Hirata +10 more
doaj +1 more source
ProNet DB: A proteome-wise database for protein surface property representations and RNA-binding profiles [PDF]
arXiv, 2022 The rapid growth in the number of experimental and predicted protein structures and more complicated protein structures challenge users in computational biology for utilizing the structural information and protein surface property representation. Recently, AlphaFold2 released the comprehensive proteome of various species, and protein surface property ...
arxiv
Pharmaceutics, 2023 Free drug concentrations are generally considered the pharmacologically active moiety and are important for cellular diffusion and distribution. Pregnancy-related changes in plasma protein binding and blood partitioning are due to decreases in plasma ...
Paola Coppola +3 more
doaj +1 more source
Crystals, 2021 CuBr(PPh3)2(4,6-dimethylpyrimidine-2-thione) (Cu-L) was synthesized by stirring CuBr(PPh3)3 and 4,6-dimethylpyrimidine-2-thione in dichloromethane. The crystal structure of Cu-L was obtained, and indicated that the complex adopts a distorted tetrahedral ...
Bandar A. Babgi +6 more
doaj +1 more source
Controlling the folding and substrate-binding of proteins using polymer brushes [PDF]
Physical Review Letters 108 208104 (2012), 2012 The extent of coupling between the folding of a protein and its binding to a substrate varies from protein to protein. Some proteins have highly structured native states in solution, while others are natively disordered and only fold fully upon binding.
arxiv +1 more source
PANDA: Predicting the change in proteins binding affinity upon mutations using sequence information [PDF]
Journal of Bioinformatics and Computational Biology, 2021, 2020 Accurately determining a change in protein binding affinity upon mutations is important for the discovery and design of novel therapeutics and to assist mutagenesis studies. Determination of change in binding affinity upon mutations requires sophisticated, expensive, and time-consuming wet-lab experiments that can be aided with computational methods ...
arxiv +1 more source
Predicting mutational effects on protein-protein binding via a side-chain diffusion probabilistic model [PDF]
arXiv, 2023 Many crucial biological processes rely on networks of protein-protein interactions. Predicting the effect of amino acid mutations on protein-protein binding is vital in protein engineering and therapeutic discovery. However, the scarcity of annotated experimental data on binding energy poses a significant challenge for developing computational ...
arxiv
Free-energy distribution of binary protein-protein binding suggests cross-species interactome differences [PDF]
PNAS 103, 11527- 11532 (2006); Aug 1, 2006 no 31, 2006 Major advances in large-scale yeast two hybrid (Y2H) screening have provided a global view of binary protein-protein interactions across species as dissimilar as human, yeast, and bacteria. Remarkably, these analyses have revealed that all species studied have a degree distribution of protein-protein binding that is approximately scale-free (varies as ...
arxiv +1 more source
FEBS Letters, EarlyView.In vivo IL‐10 produced by tissue‐resident tolDC is involved in maintaining/inducing tolerance. Depending on the agent used for ex vivo tolDC generation, cells acquire common features but prime T cells towards anergy, FOXP3+ Tregs, or Tr1 cells according to the levels of IL‐10 produced. Ex vivo‐induced tolDC were administered to patients to re‐establish/
Konstantina Morali +3 more
wiley +1 more source
Dendritic amphiphilic siRNA: Selective albumin binding, in vivo efficacy, and low toxicity
Molecular Therapy: Nucleic Acids, 2023 Although an increasing number of small interfering RNA (siRNA) therapies are reaching the market, the challenge of efficient extra-hepatic delivery continues to limit their full therapeutic potential. Drug delivery vehicles and hydrophobic conjugates are
Hassan H. Fakih +11 more
doaj